Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global commercial-stage biotechnology company committed to ...

While Moderna’s Spikevax beat Wall Street estimates in the third quarter, William Blair analyst Myles Minter in a Thursday ...

Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the ...

Moderna reported a surprise third-quarter profit on Thursday, driven by cost cutting and higher-than-expected sales of its ...

AIM Vaccine will rapidly advance the clinical trials of the mRNA respiratory syncytial virus (RSV) vaccine. As a new and globally heavyweight key vaccine product, this product is expected to become a ...

In June this year, Moderna's RSV vaccine was approved by the US FDA. Citic Securities Research report pointed out that this is the second commercial mRNA vaccine in the world after the new ...

The British pharma’s experience during the third quarter mirrored that of rival Pfizer, which also reported lower sales of ...

FDA has approved Abrysvo for active immunization for the prevention of lower respiratory tract disease caused by RSV.

New guidelines and the timing of COVID vaccinations impacted uptake of Abrysvo this year, according to a company executive.

On Thursday, Moderna Inc. (NASDAQ:MRNA) reported third-quarter revenue of $1.83 billion, beating the consensus of $1.25 ...

US mRNA specialist Moderna today announced Health Canada has approved mRESVIA (respiratory syncytial virus mRNA vaccine) for active immunization for the prevention of lower respiratory tract disease ...